肖占刚 （XIAO, Zhangang）

博士，研究员，博士研究生导师。

邮箱： xzg555898@hotmail.com

办公室地址：四川省泸州市龙马潭区商贸城17区B座3层5街川南医学转化研究院101室

个人简介：

2013 年于香港中文大学获得博士学位，完成博士后研究工作。2016 年 4 月-迄今为西南医科大学教授（三级）、博士研究生/博士后导师、川南医学转化研究院院长、川南医学转化研究院全资平台公司-四川细胞时代发展有限公司执行董事、细胞治疗与细胞药物泸州市重点实验室主任、四川科来博特科技发展有限公司执行董事、四川正雪生物科技有限公司董事长、四川细胞科技有限公司总经理、中国农工民主党党员、泸州市政协委员。获得四川省卫生健康委学术技术带头人、四川省学术技术带头人后备人选、四川省海外高层次留学人才、四川省“最美职工家庭”、酒城英才. 科技之星、泸州学术和技术带头人、泸州市五一劳动奖章、泸州市“最美科技工作者”、泸州市“最美家庭”、2022年第一、二季度“泸州好人”、西南医科大学十大杰出青年、西南医科大学科学技术先进个人等荣誉及称号；研究方向涉及肿瘤免疫、基因编辑、生物信息学等，致力于细胞治疗与细胞药物的临床转化工作。Gastroenterology、Autophagy、Cancer Research、Theranostics 等学术期刊上发表 SCI 论文 140 余篇，其中以通讯作者或第一作者发表学术论文影响因子>450、他引>3200、H指数33，是 50 余个杂志编委或特邀审稿人。迄今主持科研项目 16 项，包括国家自然科学基金项目3 项。参编英文专著 2 部，申请发明专利 10 项, 授权 4项,软件著作权 4 项。学术兼职：四川干细胞技术与细胞治疗协会副会长、中国药理学会会员、中国研究型医院学会病毒肿瘤学专业委员会常务委员、四川肿瘤药理专委会秘书长、四川药理学会理事、四川省科技青年联合会常务理事、农工党四川省委教育科技工作委员会委员、农工党泸州市第三届科技专委会副主任、成都市生物医学信息学会理事、西南医科大学药学院学术委员会委员、西南医科大学附属医院客座教授、西南医科大学附属口腔医院科研导师、古蔺县中医医院科研导师，川南医学转化研究院学术委员会副主任委员、川南医学转化研究院理事、美国癌症协会(American Association for Cancer Research, AACR）会员、欧洲肿瘤免疫学会(European Academy for Tumor Immunology, EATI)会员。获得四川省药理学会青年优秀论文奖、四川省医学科技奖青年奖二等奖、泸州市药学会优秀学术论文一等奖、泸州市科学技术协会优秀论文一等奖、中科院优秀论文奖等。

代表性论文：

1. Wu X, Huang H, Li M, Wang Y, Wu X, Wang Q, Shen J, Xiao Z, Zhao Y, Du F, Chen Y, Yang Y, Zhao Q, Zeng J, He Y, Xiao J, Excessive consumption of the sugar rich longan fruit promoted the development of nonalcoholic fatty liver disease via mediating gut dysbiosis, Food Frontiers, 2022 Accept.

2. Yang Y, Li M, Wang Q, Huang H, Zhao Y, Du F, Chen Y, Shen J, Luo H, Zhao Q, Zeng J, Li W, Chen M, Li X, Wang F, Sun Y, Gu L, Xiao Z, Wu X. Pueraria lobata starch regulates gut microbiota and alleviates high-fat high-cholesterol diet induced non-alcoholic fatty liver disease in mice, Food Research International. 2022 May.

3. Zhao Y, Guo S, Deng J, Shen J, Du F, Wu X, Chen Y, Li M, Chen M, Li X, Li W, Gu L, Sun Y, Wen Q, Li J, Xiao Z. VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. International Journal of Biological Sciences. 2022 May 29.

4. Dai Y, Yang L, Sakandar A, Zhang D, Du F, Zhang X, Zhao Y, Wang J, Zhang Z, Wu X, Li M, Ling X, Yu L, Dong L,Shen J, Xiao Z and Wen Q. Vemurafenib inhibitsimmune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer. Front. Oncol. 2022 Nov 17.

5. Chen Y, Yang Q, Xu J, Tang L, Zhang Y, Du F, Zhao Y, Wu X, Li M, Shen J, Ding R, Cao H, Li W, Li X, Chen M, Wu Z, Cho CH, Du Y, Wen Q, Xiao Z. PROTACs in Gastrointestinal Cancers. Mol Ther - Oncolytics. 2022 Oct 31.

6. Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F, Wu X, Chen Y, Li M, Chen M, Li X, Li W, Gu L, Sun Y, Zhang Z, Wen Q, Xiao Z, Li J. Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. Cancers (Basel). 2022 Aug 27.

7. Chen Y, Zheng A, Zhang Y, Xiao M, Zhao Y, Wu X, Li M, Du F, Chen Y, Chen M, Li W, Li X, Sun Y, Gu L, Xiao Z and Shen J. Dysregulation of B7 family and its association with tumor microenvironment in uveal melanoma. Front. Immunol. 2022 Oct 14.

8. Xiang S, Li J, Shen J, Zhao Y, Wu X, Li M, Yang X, Kaboli PJ, Du F, Zheng Y, Wen Q, Cho CH, Yi T, Xiao Z. Identification of  Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma. Front Immunol. 2021 Apr 7;12:653836.

9. Zhao Q, Jiang Y, Xiang S, Kaboli PJ, Shen J, Zhao Y, Wu X, Du F, Li M, Cho CH, Li J, Wen Q, Liu T, Yi T, Xiao Z. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons. Front Immunol. 2021 Mar 30;12:658753.

10. Ma Y, Zhang Y, Xiang J, Xiang S, Zhao Y, Xiao M, Du F, Ji H, Kaboli PJ, Wu X, Li M, Wen Q, Shen J, Yang Z, Li J, Xiao Z. Met   agenome Analysis of Intestinal Bacteria in Healthy People, Patients With Inflammatory Bowel Disease and Colorectal Cancer. Front Cell Infect Microbiol. 2021 Feb 26;11:599734.

11. Zhao Q, Guo J, Zhao Y, Shen J, Kaboli PJ, Xiang S, Du F, Wu X, Li M, Wan L, Li X, Wen Q, Li J, Zou C, Xiao Z. Comprehensi ve assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers. Epigenomics. 2020 Dec;12(24):2155-2171.

12. Xiang S, Ma Y, Shen J, Zhao Y, Wu X, Li M, Yang X, Kaboli PJ, Du F, Ji H, Zheng Y, Li X, Li J, Wen Q, Xiao Z. m5C RNA Meth ylation Primarily Affects the ErbB and PI3K-Akt Signaling Pathways in Gastrointestinal Cancer. Front Mol Biosci. 2020 Dec7;7:599340.

13. Jabbarzadeh Kaboli P, Afzalipour Khoshkbejari M, Mohammadi M, Abiri A, Mokhtarian R, Vazifemand R, Amanollahi S,  Yazdi Sani S, Li M, Zhao Y, Wu X, Shen J, Cho CH, Xiao Z. Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer – contradictory effects and future perspectives. Biomed Pharmacother. 2020 Jan;121:109635.

14. Jabbarzadeh Kaboli P, Salimian F, Aghapour S, Xiang S, Zhao Q, Li M, Wu X, Du F, Zhao Y, Shen J, Cho CH, Xiao Z. Akt-targ eted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy. Pharmacol Res. 2020 Jun;156:104806.

15. Jin J, Wu X, Yin J, Li M, Shen J, Li J, Zhao Y, Zhao Q, Wu J, Wen Q, Cho CH, Yi T, Xiao Z. Identification of genetic mutations in cancer: challenge and opportunity in the new era of targeted therapy, Frontiers in Oncology. 2019, Accepted.

16. Zhao Y, Zhao Q, Kaboli PJ, Shen J, Li M, Wu X, Yin J, Zhang H, Wu Y, Lin L, Zhang L, Wan L, Wen Q, Li X, Cho CH, Yi T, Li J, Xiao Z. m1A regulated genes modulate PI3K/AKT/mTOR and ErbB pathways in gastrointestinal cancer. Translational Oncology, 2019, Accepted.

17. Xu Z, Wang Y, Xiao Z, Zou C, Wu D, Yu S, Chan FL. Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer. Oncogene, 2018, Accepted

18. Zhao Y, Chen B, Shen J, Wan L, Zhu Y, Yi T, Xiao Z. The Beneficial Effects of Quercetin, Curcumin and Resveratrol in Obesity, Oxidative Medicine and Cellular Longevity, 2017. 2017：0~1459497.

19. Xu Z, Shen J, Wang H, Yi T, Yu Y, Zhu Y, Chen B, Chen J, Li L, Li M, Zuo J, Jiang H, Zhou D, Luan J, Xiao Z. Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer. OncoImmunology. 2016, 5(8):e1207841.

20. Xiao Z, Shen J, Zhang L, Li L, Li MX, Hu W, Li ZJ, Cho CH. The roles of histone demethylase UTX and JMJD3 (KDM6B) in cancers: current progress and future perspectives. Curr Med Chem. 2016, 23(32):3687-96.

21. Shen J, Xiao Z, Wu KK, Wang M, To KF, Chen Y, Yang W, Li S, Shin V, Tong J, Kang W, Zhang L, Li M, Wang L, Lu L, Chan RLY, Wong SH, Yu J, Chan MTV, Chan FKL, Sung JJY, Cheng ASL, Cho CH. Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis. Cancer Res. 2014, 75(4):1-12.

22. Xiao Z, Li CH, Chan SL, Xu F, Feng L, Wang Y, Jiang JD, Sung JJ, Cheng CH, Chen Y. A small molecule modulator of the tumor suppressor miRNA-34a inhibits the growth of hepatocellular carcinoma. Cancer Res. 2014, 74(21):6236-47.

23. Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, Chen Y. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology. 2013, 144(5):1086-97.